pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
Quick answer
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorectal Cancer (CRC), Hyperlipidemia. NovaPharmaNews links 96 clinical program(s), 10 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (51), phase 2 (26), phase 1 (17).
Company snapshot
Amgen maintains 96 tracked programs across Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorectal Cancer (CRC), Hyperlipidemia, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Dyslipidemia, Asthma, Relapsed/Refractory Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Ulcerative Colitis (UC). Momentum score: 45/100 (30-day
- 19 approved product(s) across US/EU regulatory metadata.
- 96 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Amgen. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow
- approval
Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors
- approval
FDA Shakeup: Høeg's Departure and Amgen Drug Controversy
- trial_data
MariTide Phase 2 obesity data show up to 20% weight loss at one year
- trial_data
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Recent coverage
EMA Tightens Liver Safety Checks for Tavneos After Fatal Cases
EMA's PRAC has tightened monitoring and stopping rules for Tavneos (avacopan) after reviewing serious liver injury cases, including fatal outcomes. The update adds liver injury as a rare side effect and creates a new regulatory watchpoint for Amgen and ANCA-associated vasculitis teams.
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.
FDA Shakeup: Høeg's Departure and Amgen Drug Controversy
The FDA's dismissal of acting CDER director Tracy Høeg and the revelation of 20 patient deaths linked to Amgen's Tavneos in Japan create a dual crisis of regulatory leadership and drug safety. This analysis provides key takeaways, a timeline of events, and strategic implications for pharmaceutical BD and regulatory teams.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- approved
Congress & presentations
Momentum
Proprietary activity score for Amgen.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Amgen.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Amgen?
-
Is Amgen publicly traded?
-
What drugs does Amgen develop or market?
-
What are the latest developments for Amgen?
-
What therapeutic areas does Amgen focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
Amgen maintains 96 tracked programs across Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorectal Cancer (CRC), Hyperlipidemia, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Dyslipidemia, Asthma, Relapsed/Refractory Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Ulcerative Colitis (UC). Momentum score: 45/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: Thousand Oaks USA. Ticker: E44D425.
Pipeline programs
Dazodalibep — phase phase_3, status active. Indication: Sjögren’s Syndrome. Next milestone: not disclosed (TBD).
Olpasiran, Placebo for AMG 890 — phase phase_3, status active. Indication: Cardiovascular Disease. Next milestone: not disclosed (TBD).
20220043 — phase phase_3, status active. Indication: Osteogenesis Imperfecta. Next milestone: not disclosed (TBD).
20230016 — phase phase_3, status active. Indication: Limited-Stage Small-Cell Lung Cancer (LS SCLC). Next milestone: not disclosed (TBD).
Rocatinlimab, Placebo for AMG 451 — phase phase_3, status active. Indication: Prurigo Nodularis. Next milestone: not disclosed (TBD).
20230127 — phase phase_3, status active. Indication: Early-stage Non-squamous Non-small Cell Lung Cancer. Next milestone: not disclosed (TBD).
20210098 — phase phase_3, status active. Indication: Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression. Next milestone: not disclosed (TBD).
Erenumab, Placebo for AMG 334 — phase phase_3, status active. Indication: Episodic Migraine. Next milestone: not disclosed (TBD).
20220196 — phase phase_3, status active. Indication: Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight. Next milestone: not disclosed (TBD).
20230005 — phase phase_3, status active. Indication: Metastatic castration-resistant prostate cancer (mCRPC). Next milestone: not disclosed (TBD).
20210184 — phase phase_3, status active. Indication: Chronic Weight Management. Next milestone: not disclosed (TBD).
20190172 — phase phase_3, status active. Indication: Colorectal Cancer (CRC). Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: MariTide Phase 2 obesity data show up to 20% weight loss at one year (2026-06-07).
Nova coverage: MariTide Phase 2: Amgen reports up to 20% weight loss at one year (2026-06-07).
Nova coverage: FDA Shakeup: Høeg's Departure and Amgen Drug Controversy (2026-06-04).
Nova coverage: Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors (2026-06-02).
Nova coverage: Amgen's CFO Transition: Implications for Pharma Investments (2026-05-21).
Nova coverage: Amgen's CFO Departure and Galderma's Strategic Move (2026-05-21).
Nova coverage: Amgen's CFO Departure and Galderma's New Executive: What It Means for Pharma (2026-05-20).
Nova coverage: Amgen's Expanded Crackdown on 340B Program Misuse (2026-05-17).
Registry facts
Registry profile: founded 1980; employees 40212; market cap n/a; revenue n/a; LEI 5493007TDQLA2Z7RB387; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.800.
Catalyst calendar
Catalyst: Amgen Inc Stock: Lung Cancer Setback Meets Steady Cash Flow — type approval, date 2026-05-17.
Catalyst: Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors — type approval, date 2026-06-02.
Catalyst: FDA Shakeup: Høeg's Departure and Amgen Drug Controversy — type approval, date 2026-06-04.
Catalyst: MariTide Phase 2 obesity data show up to 20% weight loss at one year — type trial_data, date 2026-06-07.
Catalyst: MariTide Phase 2: Amgen reports up to 20% weight loss at one year — type trial_data, date 2026-06-07.
Competitive peers
Peer: AstraZeneca (overlap score 40.0).
Peer: AbbVie Deutschland GmbH (overlap score 40.0).
Peer: Sunshine Guojian Pharmaceutical (overlap score 40.0).
Peer: AstraZeneca (overlap score 40.0).
Peer: Summit Therapeutics (overlap score 28.2).
Peer: Esperion Therapeutics (overlap score 23.0).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.